Insulet Corporation PODD
NASDAQ · United States · Health Technology
$130.47-2.37 (-1.78%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Insulet has seen its share price fall hard over the past year, which puts the focus squarely on whether the current market value still lines up with the cash the business is expected to generate. With the stock under pressure, the key issue now is how its cash flows compare with the price investors are paying today. Over the past 12 months, Insulet shares have declined 57.2%. This puts a lot of weight on whether the business can support the present valuation through its future cash...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 38% over the past six months while the S&P 500 was up 16.9%.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Insulet (PODD) recently reworked its financing by replacing $475 million of term loans with new debt at lower interest margins and expanding its revolving credit facility, a move that directly reshapes the balance sheet. Insulet’s refinancing lands after a tough stretch for the stock, with the share price down 52% year to date and the 1 year total shareholder return declining 58%. This points to fading momentum even before its recent index removal and conference appearances. Scan beyond...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.